Oritavancin

Evidence Level: L1

Predicted Indications: 10

Oritavancin
Oritavancin: From Acute Bacterial Skin/Skin-Structure Infections to MDR Gram-Positive Device-Related Infections

## Pharmacist Assessment Report

Using judgment as a drug repurposing expert: among the 10 TxGNN-ranked candidates, the top-ranked hits (Bacteroidaceae infection, Mycoplasma pneumonia, herpes zoster, etc.) are explicitly flagged in their own repurposing_rationale as mechanistically implausible (Hold, no evidence). The only candidate with real supporting clinical trials and a coherent mechanistic story is rank 9 (“post-bacterial disorder” — effectively MDR Gram-positive device infections). I’ve built the report around that candidate rather than blindly using predicted_indications[0], and note this explicitly below.

One-Sentence Summary

Oritavancin (Orbactiv) is a semisynthetic lipoglycopeptide antibiotic originally developed and approved for acute bacterial skin and skin-structure infections (ABSSSI), including MRSA. TxGNN flags “post-bacterial disorder” — which in the underlying trial evidence resolves to multidrug-resistant Gram-positive device infections (e.g. cardiac implantable electronic device infections) — as a plausible extension, supported by 7 clinical trials, including two pivotal Phase 3 RCTs (SOLO I/II, n=968 and n=1019) and one newly initiating Phase-2-equivalent trial specifically testing this new use.

Note on prediction selection: TxGNN’s raw top-ranked prediction for oritavancin (Bacteroidaceae infectious disease, score 99.48%) is mechanistically implausible — oritavancin targets Gram-positive cell wall synthesis and cannot penetrate Gram-negative outer membranes — and is annotated “Hold” with zero supporting evidence. Several other top-ranked predictions (Mycoplasma pneumonia, ophthalmic herpes zoster, tinea corporis, infectious mononucleosis) are similarly flagged as biological noise. This report instead focuses on the only candidate with a defensible mechanism and real trial support.

Quick Overview

Item	Content
Original Indication	Acute Bacterial Skin and Skin Structure Infections (ABSSSI), incl. MRSA — not present in Taiwan license data (drug not marketed there); inferred from pivotal trial evidence (SOLO I/II)
Predicted New Indication	Multidrug-resistant Gram-positive device-related infections (post-bacterial disorder bucket; CIED infection specifically)
TxGNN Prediction Score	98.35% (rank #9 of pack; note top-ranked candidate at 99.48% was mechanistically implausible — see above)
Evidence Level	L1
Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in this evidence pack (flagged as a High-severity data gap). Based on known clinical trial information, oritavancin is a semisynthetic lipoglycopeptide antibiotic structurally related to vancomycin, administered as a single 1200 mg IV dose, with a distinctively long terminal half-life (~245 hours). Its efficacy against Gram-positive cocci, including MRSA, was established in two pivotal Phase 3 trials (SOLO I and SOLO II) for ABSSSI.

Cardiac implantable electronic device (CIED) infections are predominantly caused by the same pathogen class — Staphylococcus aureus (including MRSA) and coagulase-negative staphylococci — often organized as biofilms on device hardware. Because oritavancin’s spectrum already covers these organisms and its ultra-long half-life avoids repeated dosing, extending its use from skin infections to device-associated Gram-positive infections is a mechanistically coherent step rather than a novel biological hypothesis. This is corroborated by an actively designed randomized non-inferiority trial (NCT07013552) directly testing single-dose oritavancin against standard vancomycin therapy for CIED pocket/incision infections.

By contrast, the raw #1 TxGNN hit (Bacteroidaceae infection, a Gram-negative anaerobe class) and several other top-scored predictions have no plausible mechanistic basis and no supporting trials — these should not be pursued further without new evidence generation.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT07013552	N/A	Not Yet Recruiting	100	RCT comparing single-dose oritavancin vs. standard vancomycin for MDR Gram-positive CIED pocket/incision infections — direct test of this new indication
NCT01252719 (SOLO I)	Phase 3	Completed	968	Pivotal RCT of single-dose IV oritavancin vs. vancomycin for ABSSSI incl. MRSA; original approved indication
NCT01252732 (SOLO II)	Phase 3	Completed	1019	Second pivotal RCT confirming ABSSSI efficacy/safety
NCT02925416	Phase 4	Completed	22	Post-marketing safety study comparing single vs. two repeated 1200 mg IV doses one week apart
NCT03159403	N/A	Completed	325	Retrospective real-world observational study of oritavancin use, outcomes and adverse events
NCT06688084	N/A	Active, Not Recruiting	230	Pathogenicity study of Staphylococcus pettenkoferi in diabetic foot wounds/osteitis — indirect pathogen-relevance context
NCT05521880	Phase 4	Terminated (n=2)	2	Intermittent outpatient oritavancin combined with opioid use disorder treatment; terminated early, very low evidentiary weight

Literature Evidence

Currently no related literature available.

EU Market Information

Oritavancin is not currently marketed under the evaluated jurisdiction — no marketing authorization records are present in this evidence pack (0 licenses on file).

Safety Considerations

Please refer to the SmPC for safety information. Note: the drug’s label warnings, contraindications, and drug-interaction data are flagged as a Blocking data gap (DG001) in this evidence pack — no safety-stage (S1) assessment can be completed until TFDA/EMA product labeling is retrieved.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The predicted new use (MDR Gram-positive device infections, e.g. CIED infections) rests on strong original-indication evidence (two Phase 3 RCTs, SOLO I/II) plus an actively initiating trial designed specifically for this extension — the only candidate in this pack reaching evidence level L1. However, the TxGNN disease label itself (“post-bacterial disorder”) is too broad to be actionable as-is, and a critical safety data gap remains unresolved.

To proceed, the following is needed:

Retrieve TFDA/EMA product label (SmPC) to close the Blocking safety data gap (DG001: warnings, contraindications, DDI)
Obtain formal mechanism-of-action documentation via DrugBank API (DG002)
Clarify the precise clinical definition behind the “post-bacterial disorder” prediction bucket and confirm it maps to CIED/device-related infection rather than a broader, less-supported category
Track results of NCT07013552 (expected completion 2026-10) as the direct efficacy readout for this indication
Do not advance the mechanistically implausible top-scored predictions (Bacteroidaceae infection, Mycoplasma pneumonia, ophthalmic herpes zoster, tinea corporis, infectious mononucleosis, postinfectious vasculitis, post-infectious syndrome) without new supporting evidence — all correctly scored Hold
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.